

# 卵巢癌精準治療研討會

The Evolving Landscape of PARP Inhibitors and the Biomarkers in Ovarian Cancer

Date：2022年8月6日(星期六)

Venue: 高雄萬豪10F 皇喜會議室B

實體+線上會議

Time	Topic	Speaker	Moderator
14:30-14:50	Registration		
14:50-15:00	Opening	饒坤銘 理事長 高雄市南屏癌症防治衛教學會	
New Era of Ovarian Cancer Maintenance Therapy			
15:00-15:30	A Walk in the PARP: Remodeling the Landscape of Newly Diagnosed Advanced Ovarian Cancer	吳貞璇 醫師 高雄長庚	林浩 醫師 高雄長庚
15:30-15:45	Discussion & QA	ALL	吳貞璇 醫師 高雄長庚 林浩 醫師 高雄長庚
15:45-16:15	PARP Inhibitors in Recurrent Ovarian Cancer: Tips From My Clinic	周宏學 醫師 林口長庚	劉文雄 醫師 高雄榮民總醫院
16:15-16:30	Discussion & QA	ALL	周宏學 醫師 林口長庚 劉文雄 醫師 高雄榮民總醫院
16:30-16:40	Break		
Ovarian Cancer Biomarkers: Current State and Future Implications			
16:40-17:10	Assessment of Recombination Repair Deficiency (HRD) Using Multidimensional Gene Panel	李健逢 醫師 奇美醫院	饒坤銘 醫師 義大癌治療醫院
17:10-17:25	Discussion & QA	ALL	李健逢 醫師 奇美醫院 饒坤銘 醫師 義大癌治療醫院
17:25-17:30	Closing	饒坤銘 理事長 高雄市南屏癌症防治衛教學會	

主辦單位：高雄市南屏癌症防治衛教學會

協辦單位：台灣武田

- 主講人：  
吳貞璇 醫師
- 題目：  
A Walk in the PARP: Remodeling the Landscape of Newly Diagnosed Advanced Ovarian Cancer
- 演講摘要：  
Epithelial ovarian cancer (EOC) is often diagnosed at an advanced stage and, despite aggressive surgical management and chemotherapy, the overall survival rate is poor. It will be critical to identify newly diagnosed patients early for PARP inhibitor treatment by carrying out biomarker testing immediately at diagnosis. Here, we review recent results with newly diagnosed advanced ovarian cancer and poly (ADP-ribose) polymerase (PARP) inhibitors as treatment and/or maintenance therapy.
  
- 主講人：  
周宏學 醫師
- 題目：  
PARP Inhibitors in Recurrent Ovarian Cancer: Tips From My Clini
- 演講摘要：  
Approximately 15% of epithelial ovarian cancers (OC) are associated with germline *BRCA1* and *BRCA2* (*BRCA*) mutations. Recent PARP inhibitor approvals (olaparib, niraparib) in the newly diagnosed EOC setting have provided new maintenance treatment options for a broader patient population. This topic will share several cases and some experience of using PARPi in OC patients.
  
- 主講人：  
李健逢 醫師
- 題目：  
Assessment of Recombination Repair Deficiency(HRD) Using Multidimensional Gene Panel
- 演講摘要：  
HRR has become a therapeutic target in *BRCA*-associated cancers. Both germline and somatic *BRCA1/2* pathogenic variants are biomarkers for administering poly ADP ribose polymerase inhibitors (PARPi). Gene panels developed by clinical molecular laboratories assess multiple potential genetic causes of a suspected disorder(s) simultaneously and reduce the cost and time of diagnostic testing.

姓名	現職	學歷	經驗
饒坤銘	<p>Attending Physician Department of Hematology/Oncology, Kaohsiung Chang Gung Memorial Hospital Current Director Breast Cancer Society of Taiwan Current Supervisor Taiwan Society of Cancer Palliative Medicine Committee Member 2015 Cancer Therapy Quality Commission, the Ministry of Health and Welfare</p>	<p>1994 MD School of Medicine, Chung Shan Medical University 2002-2004 Molecular and Cellular Oncology, M.D. Anderson Cancer Center 2011 Master Graduate Institute of Clinical Medical Sciences, Chang Gung Memorial Hospital</p>	<p>Director The Chinese Oncology Society Member Taiwan Society of Internal Medicine Member The Chinese Oncology Society Member Breast Cancer Society of Taiwan Member Taiwan Society of Cancer Palliative Medicine 1999- Attending Physician Department of Hematology/Oncology, Kaohsiung Chang Gung Memorial Hospital 2005. 07-2013. 09 Chief Department of Hematology/Oncology, Kaohsiung Chang Gung Memorial Hospital Assistant Professor and Attending Physician Chang Gung Memorial Hospital 2011 Assistant Profession Certified by the Ministry of Education</p>
吳貞璇	<p>高雄長庚 婦產部 婦 癌科主任 高雄長庚婦產部婦癌 科主治醫師</p>	<p>MD degree since June 30, 2002, Kaohsiung Medical University, Kaohsiung city. Post-Graduate</p>	<p>Resident of Department of Obstetrics and Gynecology, Kaohsiung Chang Gung Memorial Hospital,</p>

		<p>Education : PhD Candidate of Chang Gung University Academic Appointment(Include Teaching Experience): Assistant Professor of Kaohsiung Chang Gung Memorial Hospital since July, 2014</p>	<p>Kaohsiung (Jan. 1, 2004 to Dec. 31, 2006)  2. Chief Resident and Oncology Fellowship ( Jan. 1, 2007 to Dec. 31, 2008)  3. Attending physician of Department of Obstetrics and Gynecology, Kaohsiung Chang Gung Memorial Hospital (since Jan. 1, 2009~present)  4. Research Fellowship of Division of Departments of Pathology, Oncology and Gynecology/Obstetrics, Johns Hopkins University School of Medicine ( July, 1, 2011 to Oct. 31, 2012)  5. Director of Division of Gynecology Oncology, Department of Obstetrics and Gynecology, Kaohsiung Chang Gung Memorial Hospital (since July 1, 2016~present)</p>
林浩	<p>高雄長庚紀念醫院癌症中心婦癌團隊招集人 2006-  高雄長庚紀念醫院婦產部部主任 2021-  長庚大學兼任副教授</p>	台大醫學院 1993	<p>高雄長庚紀念醫院住院醫師 1993-1998  高雄長庚紀念醫院婦癌科主任 2006-2012  高雄長庚紀念醫院婦產部副主任 2014-</p>

	2017-		2020
周宏學	長庚紀念醫院婦產部 主治醫師	台北醫學院醫學系 1979 – 1986	長庚紀念醫院婦產部 婦癌團隊召集人 2007/07 至 2020 長庚紀念醫院癌症中 心委員 2009/07 至今 長庚紀念醫院體細胞 治療中心委員 2020/06 至今 國立清華大學學士後 醫學系教授及系主任 2022 年 2 月開始 醫策會西醫畢業後一 般醫學 (PGY) 訓練計 畫工作委員 2011 年 至今
劉文雄	高雄榮總 婦女醫學 部 副部主任 教育部 部定助理教 授 國防醫學院 臨床 副教授	國防醫學院醫八十 三期畢業	高雄榮總 婦女醫學 部 部主任、婦科主任 任 高雄榮總 癌症中心 主任
李健逢	2021~ 醫學研究部 部長	1995~2002 年 高雄 醫學大學醫學系 (醫學士) 2009~2012 年 國立 中山大學生物醫學 研究所 (博士)	2007-present 奇美醫 院病理部主治醫師 2002-2007 年 奇美醫 院病理部住院醫師 2007-2009 年 奇美醫 院臨床病理科主治醫 師 2009-2018 年 奇美醫 院臨床病理科主任 2018-2021 年 奇美醫 院病理中心部長